References
Barbash GI, Glied SA (2010) New technology and health care costs—the case of robot-assisted surgery. N Engl J Med 363(8):701–704
Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7(6):723–726
Stafford RS, Wagner TH, Lavori PW (2009) New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N Engl J Med 361(13):1230–1233
Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: Is evidence from a randomized trial true? Ann Surg 249(4):695–696
Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10(4):473–476
Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555
Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350
Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651
Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22(5):1402–1404
Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: May it improve also survival? Surg Endosc 22(5):1405–1406
Bianchi PP, Ceriani C, Locatelli A, Spinoglio G, Zampino MG, Sonzogni A, Crosta C, Andreoni B (2010) Robotic versus laparoscopic total mesorectal excision for rectal cancer: comparative analysis of oncological safety and short-term outcomes. Surg Endosc 24(11):2888–2894
No authors listed (2010) Human genome: genomes by the thousand. Nature 467:1026–1027
Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250
Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995; author reply 1995–1996
Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11(8):1039–1043
Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545
Roukos DH (2010) Systems medicine: A real approach for future personalized oncology? Pharmacogenomics 11(3):283–287
Ziogas D, Roukos DH (2009) CDH1 testing: Can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681
Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7(4):347–350
Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126
Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943
Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10:718–721
Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609
Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7(4):253–255
Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15
Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11(2):81–92
Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4(4):583–586
Conflict of interest
Author Christof Hottenrott has no conflicts of interest or financial ties to disclose.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hottenrott, C. Robotic versus laparoscopic surgery for rectal cancer and cost-effectiveness analysis. Surg Endosc 25, 3954–3956 (2011). https://doi.org/10.1007/s00464-011-1808-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00464-011-1808-9